Nkarta, Inc. (NKTX) compared with its closest peers (PEPG, DERM, CRBP, TNXP, ORMP). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| PepGen Inc. (PEPG) | $216.78M | -3.1 |
| Journey Medical Corporation (DERM) | $213.21M | -16.4 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | $201.15M | -1.4 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | $200.38M | -1.1 |
| Oramed Pharmaceuticals Inc. (ORMP) | $199.67M | 3.9 |
| Korro Bio, Inc. (KRRO) | $193.49M | -0.6 |
| Tharimmune, Inc. (CNTN) | $174.50M | — |
| Cue Biopharma, Inc. (CUE) | $174.06M | -1.1 |
| Lifecore Biomedical, Inc. (LFCR) | $172.61M | -15.2 |
| Indaptus Therapeutics, Inc. (INDP) | $170.55M | -0.1 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
NKTX overview · NKTX earnings · NKTX financials · NKTX KPIs · NKTX investor relations · NKTX ownership · NKTX filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.